Nanocrystal Delivery of Hydrophobic Anticancer Drugs

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$174,273.00
Award Year:
2010
Program:
STTR
Phase:
Phase I
Contract:
1R41EB013482-01A1
Award Id:
n/a
Agency Tracking Number:
R41EB013482
Solicitation Year:
2010
Solicitation Topic Code:
NIBIB
Solicitation Number:
PA09-081
Small Business Information
500 Industrial Drive, Lawrenceburg, IN, 47025-2971
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
783437804
Principal Investigator:
FRANK BEDU-ADDO
(513) 755-3065
fbeduaddo@pdsbiotech.com
Business Contact:
FRANK ADDO
(812) 537-0779
fbeduaddo@pdsbiotech.com
Research Institute:
University Of North Carolina Chapel Hill

Office Of Sponsored Research
CHAPEL HILL, NC, 27599-
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Nanosystems have been extensively investigated for drug delivery; however, there is a challenge in transferring nanotechnology from research laboratories into pharmaceutical industry. The scientific basis for this proposal originated from our three-phase nanoparticle engineering (3PNE) method recently developed which includes phase 1, amorphous precipitate; phase 2, hydrated amorphous aggregate; and phase 3, stabilized nanocrystals (NCs). The 3PNE has been applied to the development of nanocrystals for the effective delivery of the anticancer drug, Paclitaxel (PTX). This nanocrystal is unique in its simplicity, low toxicity and its high drug loading ratio. The goal of this application is to further explore this novel nanotechnology and its feasibility for commercialization for intravenous PTX delivery. To achieve this goal, the following aims are proposed. Aim 1: Develop a technology to pave the way for large scale production of PTX nanocrystals. Aim 2: Characterize thePTX nanocrystals for their pharmaceutical kinetics, bio-distribution and acute toxicity in animals. Aim 3: Establish targeted PTX nanocrystals to further increase the anti-tumor efficiency. We believe that the success of this project will accelerate the commercialization of this nanotechnology for cancer therapy. PUBLIC HEALTH RELEVANCE: Paclitaxel nanocrystals developed using the novel three-phase nanoparticle engineering (3PNE) technology have significant potential for commercialization due to their simplicity, low toxicity, and cost effectiveness. The technology lowers drug dosing and improves efficacy.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government